An age of asphyxiation - a compelling op ed by @NMPulmCritCare @JustinFiala - beyond proud to work with him! chicago.suntimes.com/2020/6/3/21279… via @SunTimes

In a time when division threatens to tear the country apart, Northwestern Medicine is unified in our commitment to make the lives we touch and the communities we serve better. #WhiteCoatsForBlackLives

I pledge to oppose racism and hate through active allyship, continuous unlearning, learning, and listening. Join me by nominating 5 others to do the same. Fred S McLafferty Jamie Nomitch @JafariLua Chetan Vakkalagadda, MD Jayson Baman

We need physicians of color in all medical specialties, now more than ever. The move to P/F for USMLE Step 1 could bring us closer to achieving #DiversityinMedicine. Honored to share thoughts with Quinn Capers, IV + Utibe R. Essien, MD MPH. Out now in NEJM: nejm.org/doi/full/10.10…

A rich 1-pager #SARSCoV2 vaccine infographic (I've divided in 2) which nicely deconstructs the complex, high- velocity race washingtonpost.com/graphics/2020/… by aaron steckelberg carolyn johnson Gabriel Florit Chris Alcantara Post Graphics

We discuss the triple combination of Nivolumab + Ipilimumab + Cabozantinib in Advanced #RenalCellCarcinoma: Results from a Discontinued Arm of the Phase 3 #CheckMate9ER ⁦Elias Chandran, MBBS⁩ Giovanni Maria Iannantuono Nicholas Simon ⁦⁦UroToday.com⁩ ⁦ urotoday.com/recent-abstrac…

We have a fantastic team of rising ⭐️s Elias Chandran, MBBS Giovanni Maria Iannantuono Nicholas Simon @NCIResearchCtr presenting our #BladderCancer posters on 1]mismatch repair deficiency & MSI 2]Olaparib biomarker-selected TPS 3]M7824 +NHS-IL12 +/-XRT study 4] AI with PET/CT ASCO #ASCO23

Congratulations to Dr. Apolo Andrea Apolo, M.D. National Cancer Institute and team.

This Friday at @asco #GU24 Dr. Andrea Apolo Andrea Apolo, M.D. NCI CCR GU Malignancies @NCIResearchCtr will present the results from the phase 3 AMBASSADOR of adjuvant Pembro in urothelial carcinoma Alliance for Clinical Trials in Oncology

Great audience participation in #AUA24 #UTUC course with ⁦Nicholas Simon⁩ ⁦Hong Truong⁩ Jonathan Coleman. Much progress and much on the horizon! ⁦Amer. Urol. Assn.⁩ ⁦Penn State Urology⁩ ⁦National Cancer Institute⁩ ⁦Memorial Sloan Kettering Cancer Center⁩

A study in BMJ Oncology suggests MMR-D/MSI-H urothelial cancer may confer high sensitivity to immunotherapy. This could spare patients the morbidity of radical surgery and the toxicities of chemotherapy. Andrea Apolo, M.D. Elias Chandran, MBBS Giovanni Maria Iannantuono bmjoncology.bmj.com/content/3/1/e0…

Very proud of this #ClinicalTrial of Cabozantinib/Nivolumab #CaboNivo & Cabozantinib/ Nivolumab/Ipilimumab #CaboNivoIpi published Journal of Clinical Oncology, that includes #rareGUtumors & took years to complete but laid the foundation for many future trials in oncology gcc02.safelinks.protection.outlook.com/?url=https%3A%…

Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. What is most important to patients regarding their experiences of disease burden and treatment #BladderCancer ⁦Nicholas Simon⁩ link.springer.com/article/10.100…

Calling GU junior faculty & fellows! 📣 Apply for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-3/8, led by me & Zach Klaassen. Secure your spot for 2 days of professional development & networking: forms.gle/jMG7iKfAYomuad… OncoAlert YUO #SUO24

Happy holidays from the NCI #BladderCancer Research Team! NCI CCR GU Malignancies @NCICCR_MOS @NCICCR_UroOnc National Cancer Institute

We have several accruing #ClinicalTrials for patients with #SmallCell #BladderCancer 1. #Lurbi +/- #Avelumab LASER clinicaltrials.gov/study/NCT06228… 2. #SG +/- #Atezo SMART clinicaltrials.gov/study/NCT06161… 3. #CaboNivoIpi ICONIC clinicaltrials.gov/study/NCT03866… [email protected] / ☎️240-760-6006

Standing in for Dr Simon and Andrea Apolo, M.D. for our poster at #GU25 ASCO Alliance for Clinical Trials in Oncology regarding rare cancer treatment preferences , the right answer, we need trials!

Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High ASCO #ASCO25 Caris Life Sciences

Opening soon at the NIH!! E-VIRTUE, A Phase 2 Trial of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors. Andrea Apolo, M.D. National Cancer Institute Nicholas Simon Dr. Andre R. Kydd Saad Atiq doi.org/10.1080/147966…

#BCANTT25 proud of our Medical Oncology fellow Miles Hsu who received the the 2025 John Quale Travel award for our work in the development of a clinical trial for bladder preservation in MIBC. Congratulations to him and to all the outstanding fellows! Bladder Cancer Advocacy Network